Quantcast
Last updated on April 19, 2014 at 8:28 EDT

Latest Risperidone Stories

2013-11-06 23:29:36

The November 4, 2013, announcement by the Department of Justice that J&J will pay more than $2 Billion to settle civil and criminal claims against it reflects the severity of the damage done to patients and society’s demand that pharmaceutical companies follow regulations, according to plaintiffs’ attorney Derek T. Braslow of Pogust Braslow & Millrood. Philadelphia, PA (PRWEB) November 06, 2013 Pennsylvania attorney Derek T. Braslow said today that untold numbers of people...

2013-11-05 23:26:47

The Agreement Settles Charges that Johnson & Johnson Illegally Marketed Risperdal, Invega and Natracor for Off-Label Use and Paid Kick-Backs to Physicians to Drive Sales of Risperdal and Invega, Alonso Krangle LLP reports. New York, NY (PRWEB) November 05, 2013 Johnson & Johnson has agreed to pay $2.2 billion to settle charges with the U.S. Department of Justice (DOJ) over the alleged illegal marketing of Risperdal, Invega and Natrecor, Alonso Krangle LLP reports. In a press...

2013-11-05 23:22:03

In a release from the U.S. Department of Justice (DOJ), Johnson & Johnson will pay out more than $2.2 Billion after allegations of promotion of Risperdal, Invega and Natrecor for uses not approved as safe and effective and physician kickbacks pertaining to the prescription drugs. Columbus, OH (PRWEB) November 05, 2013 Risperdal lawsuits may take a new turn with news coming out of the U.S. Department of Justice (DOJ), according to the experienced personal injury law firm of Wright...

2013-11-05 23:01:26

Global healthcare giant Johnson & Johnson and its Janssen subsidiary will pay more than $2.2 billion to settle allegations related to the off-label marketing of the anti-psychotic drug Risperdal, plus two other drugs. Parker Waichman LLP commends several whistleblowers who will be awarded millions of dollars in compensation for their efforts to expose alleged fraud. New York, New York (PRWEB) November 05, 2013 Parker Waichman LLP, a national law firm dedicated to protecting the rights...

2013-11-05 16:27:39

FORT LAUDERDALE, Fla., Nov. 5, 2013 /PRNewswire/ -- South Florida consumer advocate and leading false claims attorney Gary M. Farmer, Jr., a partner with Farmer, Jaffe, Weissing, Edwards, Fistos & Lehrman, P.L., has successfully litigated his third major false claims case against a global pharmaceutical company. Today, the United States Department of Justice announced a settlement against pharmaceutical giant Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals Inc. Johnson...

2013-11-04 23:20:22

Sheller, P.C. Law Firm Represents “First to File” Pharmaceutical Industry Whistleblower for Record-Breaking $2+ Billion Settlement bringing Firm’s Recoveries to over $6 Billion Philadelphia, PA (PRWEB) November 04, 2013 Healthcare giant Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals (J&J), will pay the federal government more than $2 billion in civil settlement and criminal fines to settle charges that Janssen Pharmaceuticals illegally marketed the blockbuster...

2013-11-04 23:01:50

The Firm is investigating an alleged association between Risperdal and gynecomastia, or male breast growth. New York, NY (PRWEB) November 04, 2013 As Risperdal lawsuits (http://www.therisperdallawsuit.com) involving allegations that use of the antipsychotic drug caused gynecomastia, or male breast growth, continue to mount in courts throughout the country, Bernstein Liebhard LLP notes that Johnson & Johnson has agreed to pay $2.2 billion to settle a government probe into the marketing...

2013-11-04 23:00:33

http://www.DrugNews.net is the web’s premier source for prescription drug warnings, research, side effects and legal news. Visit the DrugNews Center today. New York, NY (PRWEB) November 04, 2013 The medication safety advocates at DrugNews.net are announcing the launch of a new resource site for patients taking the antipsychotic drug Risperdal. Information will be available on studies into the drug’s side effects, the issuance of safety alerts, as well as legal news for any injury...

2013-11-04 12:28:23

NEW BRUNSWICK, N.J., Nov. 4, 2013 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) and its subsidiaries, Janssen Pharmaceuticals, Inc. and Scios Inc., today announced they have finalized previously disclosed settlement agreements with the U.S. Department of Justice (DOJ) and 45 states resolving federal investigations and state Medicaid claims related to past promotional practices of RISPERDAL(®) from 1999 through 2005, and other matters. The resolution includes total settlement...

2013-10-24 23:02:30

Bernstein Liebhard LLP is actively investigating potential Risperdal gynecomastia lawsuit claims on behalf of men and boys who may have developed male breast growth after taking the antipsychotic drug. New York, NY (PRWEB) October 24, 2013 A new Risperdal lawsuit (http://www.therisperdallawsuit.com/) alleging gynecomastia, or male breast growth, has been filed in a consolidated litigation underway in Pennsylvania state court, Bernstein Liebhard LLP reports. According to recent court...